Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 16;17(4):e2006421. doi: 10.1371/journal.pbio.2006421

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

PMC Copyright notice

Fig 3 — (A) Effect of intracerebroventricular infusion of OXT on alcohol reinforcers earned by dependent rats in 30-min alcohol self-administration sessions. (B) Effect of peripheral administration (intraperitoneal) of the OXT receptor antagonist L-371,257 that does not cross the blood-brain barrier on the ability of intranasal OXT to reduce alcohol reinforcers earned by dependent rats in 30-min alcohol self-administration sessions. (C) Effect of central (intracerebroventricular) administration of the OXT receptor agonist (PF-06655075, a long-acting, large molecule that does not cross the blood-brain barrier), on reinforcers earned by dependent rats in 30-min alcohol self-administration sessions. (D) Effect of systemic (subcutaneous) administration of PF-06655075 on reinforcers earned by dependent rats in 30-min alcohol self-administration sessions. *Significantly different from baseline or VEH condition (both in the case of panel C) (p < 0.05). OXT, oxytocin; VEH, vehicle.